Benzinga | Jan 11, 2022 08:06AM EST

Aldeyra Therapeutics Announces Top-Line Data From Phase 2 Dry Eye Chamber Clinical Trial Of Reproxalap; Says Reproxalap Patient-Reported Ocular Discomfort And Itching Were Statistically Lower Than With Xiidra

* Reproxalap Statistically Lower than Xiidrafor the Two Endpoints of the Trial: Ocular Discomfort (p=0.002) and Ocular Itching (p=0.01)

* Results Consistent with Data from Post-Acute Ocular Tolerability Comparison of Reproxalap and Xiidra in Patients with Dry Eye Disease

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced positive top-line data from a Phase 2 clinical trial comparing ocular discomfort and itching symptom scores of reproxalap ophthalmic solution 0.25% (reproxalap), an investigational new drug, versus Xiidra(r) (lifitegrast ophthalmic solution 5%) in patients with dry eye disease. Patient-reported ocular discomfort (p=0.002) and itching (p=0.01) were statistically lower with reproxalap than with Xiidra.